ChimeriVax-West Nile vaccine.
Acambis (formerly Peptide Therapeutics) is developing ChimeriVax-West Nile, a recombinant live-attenuated vaccine which incorporates their ChimeriVax platform technology, for the potential prevention of West Nile virus infection [373463], [328969]. A phase II clinical trial to assess the safety, tolerability and immunogenicity of different doses of ChimeriVax-West Nile is underway [642090], [775386].